Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Intuitive Surgical Inc’s dV5 Adoption Hits Critical Mass—But Can It Justify the Premium Multiple as Trade-Ins Slow and Rivals Circle?
Intuitive Surgical delivered a strong Q2F25 with $2.44B in revenue (+21% YoY) and EPS of $2.19 (+23% YoY), driven by 17% procedure growth and a 16% increase in da Vinci system placements. The da Vinci 5 cycle is gaining momentum with 180 units placed and early trade-in velocity (83 units vs. 21 YoY), supporting favorable utilization and validation of new features like Force Feedback and Case Insights. Instrument and accessory revenue rose 18%, reflecting procedural durability even amid bariatric headwinds, while recurring revenue held at 85% of total, reinforcing business model resilience. Gross margin compressed 210bps to 67.9% due to dV5 and Ion mix, though FY margin guidance was raised modestly, and operating margin surprised positively at 39% on contained OpEx growth. International demand remains choppy—Japan and China lag on system placements, while India and Eastern Europe offer greenfield upside. SP and Ion continue to scale, but remain early-stage. The ecosystem’s differentiation lies in software, analytics, and surgical precision, yet the stock’s valuation reflects high expectations. As trade-in pace moderates and gross margin tailwinds ease, can Intuitive maintain enough system velocity, clinical edge, and monetization breadth to defend its premium multiple against emerging competition and a flattening innovation curve?
